VG5Q Angiogenic Factor Modulation for Vascular Growth Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targets for modulating angiogenesis, particularly in conditions characterized by excessive or insufficient blood vessel growth, such as cancer and ischemic diseases, where existing angiogenic factors do not adequately address the need for precise regulation of endothelial cell proliferation and apoptosis.
Innovation Solution
Identification and characterization of a novel angiogenic factor, VG5Q, which plays a critical role in vascular morphogenesis and angiogenesis, allowing for the development of therapeutic compositions and methods to regulate its activity, including expression vectors, antibodies, and RNAi sequences to modulate VG5Q expression for treating angiogenesis-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing angiogenic factors are used to regulate blood vessel growth, then some angiogenic activity can be achieved, but precise regulation of endothelial cell proliferation and apoptosis is insufficient
Solution Approach 1:
The patent identifies VG5Q as a novel angiogenic factor with specific molecular characteristics (molecular weight of approximately 87 kDa, specific amino acid sequence) that differentiate it from existing angiogenic factors. By changing the parameter of factor specificity and introducing a new molecular entity with unique properties, the patent achieves both precise regulation and effective angiogenic activity that previous factors could not provide simultaneously
2Adaptability or versatility
If angiogenesis is stimulated to promote blood vessel growth, then blood flow improvement is achieved, but excessive vessel growth occurs in diseases like cancer
Solution Approach 1:
The patent introduces VG5Q as a specific molecular mediator that can be targeted to control angiogenesis. By identifying this intermediate factor in the angiogenic pathway, the invention enables precise intervention - either promoting or inhibiting blood vessel growth depending on the disease state, thereby achieving adaptability while avoiding harmful excessive growth through targeted modulation of this specific mediator
3Reliability
If angiogenesis inhibitors are used to stop excessive blood vessel growth, then tumor progression is reduced, but insufficient angiogenesis occurs in ischemic diseases
Solution Approach 1:
The patent enables dynamic control of angiogenesis by targeting VG5Q, a key factor in the angiogenic process. The therapeutic compositions can be adjusted to either stimulate or inhibit VG5Q activity depending on the clinical need - promoting blood vessel formation in ischemic diseases or suppressing excessive growth in cancer - thereby achieving reliable balance control while maintaining appropriate productivity levels for each disease state
Data Source
AI summary
This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in newly formed endothelial tubes, and no nuclear staining after 24 hours; is expressed in endothelial cells; is secreted during angiogenesis; and interacts with TWEAK. The invention also provides for expression vectors containing nucleic acid sequences encoding VG5Q protein, and host cells containing one or more expression vectors for the recombinant expression of VG5Q. The invention also provides for methods of using VG5Q for the diagnosis and treatment of angiogenesis-mediated diseases or disorders.